Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 6Myelodysplastic Syndromes 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Leukemia 1

Interventions

Cyclophosphamide 34fludarabine phosphate 33Cytarabine 33fludarabine 26Peripheral Blood Stem Cell Transplantation 23Filgrastim 23Methotrexate 18Busulfan 17Rituximab 15Cyclosporine 14Azacitidine 14Melphalan 13Clofarabine 13Tacrolimus 12venetoclax 11Mycophenolic Acid 10Etoposide 10Alemtuzumab 10Radiotherapy 9Imatinib Mesylate 8Granulocyte Colony-Stimulating Factor 8Decitabine 8ruxolitinib 7Whole-Body Irradiation 7Stem Cell Transplantation 7Idarubicin 7Dexamethasone 7Antilymphocyte Serum 7aldesleukin 6Mitoxantrone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia × midostaurin × Clear all
NCT01202877 2018-10-16

PKC412 and 5-Azacytidine

M.D. Anderson Cancer Center

Phase 1/2 Completed
54 enrolled 8 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡